Androgen Receptor is Causally Involved in the Homeostasis of the Human Prostate Endothelial Cell
Overview
Authors
Affiliations
Androgen deprivation causes a reduction of blood flow in the prostate gland that precedes temporally apoptosis of the epithelium. The acute response of prostate endothelial cells to androgen deprivation suggested they represent a primary target for androgen. However, rat prostate endothelial cells were reported not to express androgen receptor (AR), and the role of the androgen axis in human prostate endothelial cell (HPEC) homeostasis was poorly characterized. In this study AR expression was detected in HPEC in vivo in clinical specimens of benign prostate and prostate cancer, and AR function as a transcription factor was demonstrated in HPEC in primary xenografts of human benign prostate tissue transplanted into severe combined immunodeficient mice by iv administration of adenoviral mouse mammary tumor virus-driven luciferase expression vector. AR expression and functionality were maintained in vitro in primary cultures of HPEC that coexpressed CD31, CD34, von Willebrand factor, intercellular adhesion molecule, vascular endothelial growth factor receptor 1, and vascular endothelial growth factor receptor 2 but did not express prostate-specific antigen. AR expression in primary cultures of HPEC isolated from surgical specimens of benign prostate was validated using RT-PCR, cDNA sequencing, immunocytochemistry, and Western blot analyses. Scatchard analyses demonstrated a single ligand-binding site for R1881 in primary cultures of HPEC, with dissociation constant of 0.25 nm, and AR-mediated transcriptional activity was demonstrated using adenoviral mouse mammary tumor virus-driven luciferase reporters. Dihydrotestosterone increased proliferation in primary cultures of HPEC in a dose-dependent manner without modulating endothelial tube formation in Matrigel (BD Biosciences, Bedford, MA). Therefore, HPECs express functional AR, and androgen plays a direct role in modulating HPEC biology.
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities.
Dotto G, Buckinx A, Ozdemir B, Simon C Nat Rev Cancer. 2024; 25(2):93-108.
PMID: 39587300 DOI: 10.1038/s41568-024-00772-w.
Galuh S, Meijer O, Brinks J, Schlingemann R, Boon C, Verdijk R Invest Ophthalmol Vis Sci. 2024; 65(8):5.
PMID: 38958971 PMC: 11223622. DOI: 10.1167/iovs.65.8.5.
Sex differences in cancer and immunotherapy outcomes: the role of androgen receptor.
Zhao J, Wang Q, Tan A, Loh C, Toh H Front Immunol. 2024; 15:1416941.
PMID: 38863718 PMC: 11165033. DOI: 10.3389/fimmu.2024.1416941.
Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer.
Leach D, Fernandes R, Bevan C Endocr Oncol. 2023; 2(1):R112-R131.
PMID: 37435460 PMC: 10259329. DOI: 10.1530/EO-22-0065.
Lin M, Sun X, Lv L Mol Ther Oncolytics. 2023; 29:91-106.
PMID: 37215386 PMC: 10199166. DOI: 10.1016/j.omto.2023.04.007.